Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 25

1.

Mean Platelet Volume Predicts Vascular Access Events in Hemodialysis Patients.

Lano G, Sallée M, Pelletier M, Bataille S, Fraisse M, Berda-Haddad Y, Brunet P, Burtey S.

J Clin Med. 2019 May 4;8(5). pii: E608. doi: 10.3390/jcm8050608.

2.

Myeloma cast nephropathy: the dusk of high cutoff haemodialysis.

Sallée M, Burtey S.

Lancet Haematol. 2019 Apr;6(4):e174-e176. doi: 10.1016/S2352-3026(19)30044-4. Epub 2019 Mar 11. No abstract available.

PMID:
30872076
3.

Endothelium structure and function in kidney health and disease.

Jourde-Chiche N, Fakhouri F, Dou L, Bellien J, Burtey S, Frimat M, Jarrot PA, Kaplanski G, Le Quintrec M, Pernin V, Rigothier C, Sallée M, Fremeaux-Bacchi V, Guerrot D, Roumenina LT.

Nat Rev Nephrol. 2019 Feb;15(2):87-108. doi: 10.1038/s41581-018-0098-z. Review.

PMID:
30607032
4.

Thrombotic microangiopathy associated with gemcitabine use: Presentation and outcome in a national French retrospective cohort.

Daviet F, Rouby F, Poullin P, Moussi-Francès J, Sallée M, Burtey S, Mancini J, Duffaud F, Sabatier R, Pourroy B, Grandvuillemin A, Grange S, Frémeaux-Bacchi V, Coppo P, Micallef J, Jourde-Chiche N.

Br J Clin Pharmacol. 2019 Feb;85(2):403-412. doi: 10.1111/bcp.13808. Epub 2018 Dec 18.

PMID:
30394581
5.

Aryl hydrocarbon receptor is activated in patients and mice with chronic kidney disease.

Dou L, Poitevin S, Sallée M, Addi T, Gondouin B, McKay N, Denison MS, Jourde-Chiche N, Duval-Sabatier A, Cerini C, Brunet P, Dignat-George F, Burtey S.

Kidney Int. 2018 Apr;93(4):986-999. doi: 10.1016/j.kint.2017.11.010. Epub 2018 Feb 1.

PMID:
29395338
6.

Clinical and genetic heterogeneity in familial steroid-sensitive nephrotic syndrome.

Dorval G, Gribouval O, Martinez-Barquero V, Machuca E, Tête MJ, Baudouin V, Benoit S, Chabchoub I, Champion G, Chauveau D, Chehade H, Chouchane C, Cloarec S, Cochat P, Dahan K, Dantal J, Delmas Y, Deschênes G, Dolhem P, Durand D, Ekinci Z, El Karoui K, Fischbach M, Grunfeld JP, Guigonis V, Hachicha M, Hogan J, Hourmant M, Hummel A, Kamar N, Krummel T, Lacombe D, Llanas B, Mesnard L, Mohsin N, Niaudet P, Nivet H, Parvex P, Pietrement C, de Pontual L, Noble CP, Ribes D, Ronco P, Rondeau E, Sallee M, Tsimaratos M, Ulinski T, Salomon R, Antignac C, Boyer O.

Pediatr Nephrol. 2018 Mar;33(3):473-483. doi: 10.1007/s00467-017-3819-9. Epub 2017 Oct 23.

PMID:
29058154
7.

[Uro- and nephrotoxic effects of drugs of abuse: Literature review and pharmaco-epidemiological survey in France and in the Marseille area].

Gully M, Frauger É, Spadari M, Pochard L, Pauly V, Romain F, Gondouin B, Sallée M, Moussi-Frances J, Burtey S, Dussol B, Daniel L, Micallef J, Jourde-Chiche N.

Nephrol Ther. 2017 Nov;13(6):429-438. doi: 10.1016/j.nephro.2017.01.024. Epub 2017 Sep 27. Review. French.

PMID:
28958905
8.

Serum microRNAs are altered in various stages of chronic kidney disease: a preliminary study.

Brigant B, Metzinger-Le Meuth V, Massy ZA, McKay N, Liabeuf S, Pelletier M, Sallée M, M'Baya-Moutoula E, Paul P, Drueke TB, Burtey S, Metzinger L.

Clin Kidney J. 2017 Aug;10(4):578. doi: 10.1093/ckj/sfx068. Epub 2017 Jul 9.

9.

Indole 3-acetic acid, indoxyl sulfate and paracresyl-sulfate do not influence anemia parameters in hemodialysis patients.

Bataille S, Pelletier M, Sallée M, Berland Y, McKay N, Duval A, Gentile S, Mouelhi Y, Brunet P, Burtey S.

BMC Nephrol. 2017 Jul 26;18(1):251. doi: 10.1186/s12882-017-0668-5. Erratum in: BMC Nephrol. 2017 Oct 4;18(1):306.

10.

Serum microRNAs are altered in various stages of chronic kidney disease: a preliminary study.

Brigant B, Metzinger-Le Meuth V, Massy ZA, McKay N, Liabeuf S, Pelletier M, Sallée M, M'Baya-Moutoula E, Paul P, Drueke TB, Burtey S, Metzinger L.

Clin Kidney J. 2017 Feb;10(1):30-37. doi: 10.1093/ckj/sfw060. Epub 2016 Jul 4. Retraction in: Clin Kidney J. 2017 Aug;10 (4):578.

11.

Apheresis to treat systemic vasculitis.

Moussi-Frances J, Sallée M, Jourde-Chiche N.

Joint Bone Spine. 2018 Mar;85(2):177-183. doi: 10.1016/j.jbspin.2017.06.001. Epub 2017 Jun 7.

PMID:
28602810
12.

Trends in Survival and Renal Recovery in Patients with Multiple Myeloma or Light-Chain Amyloidosis on Chronic Dialysis.

Decourt A, Gondouin B, Delaroziere JC, Brunet P, Sallée M, Burtey S, Dussol B, Ivanov V, Costello R, Couchoud C, Jourde-Chiche N.

Clin J Am Soc Nephrol. 2016 Mar 7;11(3):431-41. doi: 10.2215/CJN.06290615. Epub 2016 Jan 4.

13.

Plasma Xanthine Oxidase Activity Is Predictive of Cardiovascular Disease in Patients with Chronic Kidney Disease, Independently of Uric Acid Levels.

Gondouin B, Jourde-Chiche N, Sallee M, Dou L, Cerini C, Loundou A, Morange S, Berland Y, Burtey S, Brunet P, Guieu R, Dussol B.

Nephron. 2015;131(3):167-74. doi: 10.1159/000441091. Epub 2015 Oct 2.

PMID:
26426087
14.

[Antiphospholipids antibodies and hemodialysis: a frequent association linked to arteriovenous fistula thrombosis].

Bataille S, Burtey S, Decourt A, Frère C, Henneuse A, Aillaud MF, Morange P, Bardin N, Duval A, Sallée M, Jourde-Chiche N, Gondouin B, Samson L, Cohen J, Berland Y, Brunet P.

Nephrol Ther. 2015 Feb;11(1):27-33. doi: 10.1016/j.nephro.2014.08.005. Epub 2014 Nov 26. French.

PMID:
25457108
15.

The cardiovascular effect of the uremic solute indole-3 acetic acid.

Dou L, Sallée M, Cerini C, Poitevin S, Gondouin B, Jourde-Chiche N, Fallague K, Brunet P, Calaf R, Dussol B, Mallet B, Dignat-George F, Burtey S.

J Am Soc Nephrol. 2015 Apr;26(4):876-87. doi: 10.1681/ASN.2013121283. Epub 2014 Aug 21.

16.

The aryl hydrocarbon receptor-activating effect of uremic toxins from tryptophan metabolism: a new concept to understand cardiovascular complications of chronic kidney disease.

Sallée M, Dou L, Cerini C, Poitevin S, Brunet P, Burtey S.

Toxins (Basel). 2014 Mar 4;6(3):934-49. doi: 10.3390/toxins6030934. Review.

17.

Alternative splicing events is not a key event for gene expression regulation in uremia.

Sallée M, Fontès M, Louis L, Cérini C, Brunet P, Burtey S.

PLoS One. 2013 Dec 16;8(12):e82702. doi: 10.1371/journal.pone.0082702. eCollection 2013.

18.

Indolic uremic solutes increase tissue factor production in endothelial cells by the aryl hydrocarbon receptor pathway.

Gondouin B, Cerini C, Dou L, Sallée M, Duval-Sabatier A, Pletinck A, Calaf R, Lacroix R, Jourde-Chiche N, Poitevin S, Arnaud L, Vanholder R, Brunet P, Dignat-George F, Burtey S.

Kidney Int. 2013 Oct;84(4):733-44. doi: 10.1038/ki.2013.133. Epub 2013 May 1.

19.

Thrombocytopenia is not mandatory to diagnose haemolytic and uremic syndrome.

Sallée M, Ismail K, Fakhouri F, Vacher-Coponat H, Moussi-Francés J, Frémaux-Bacchi V, Burtey S.

BMC Nephrol. 2013 Jan 8;14:3. doi: 10.1186/1471-2369-14-3.

20.

Myocardial infarction is a complication of factor H-associated atypical HUS.

Sallée M, Daniel L, Piercecchi MD, Jaubert D, Fremeaux-Bacchi V, Berland Y, Burtey S.

Nephrol Dial Transplant. 2010 Jun;25(6):2028-32. doi: 10.1093/ndt/gfq160. Epub 2010 Mar 19.

PMID:
20305136

Supplemental Content

Loading ...
Support Center